Supplementary Table S4. Neutrophil/granulocyte CTCAE grade at baseline and after cycle 1 in patients with liver impairment

	Normal	Liver Impairment		
n (%)	**Group A**	**Group B**	**Group C**	**Group D**
	(n=540)	**(n=292)**	**(n=440)**	**(n=34)**
Baseline				
n	538	286	433	34
Any grade	26 (4.8)	14 (4.9)	17 (3.9)	2 (5.9)
Grade 1	25 (4.6)	13 (4.5)	16 (3.7)	1 (2.9)
Grade 2	1 (0.2)	1 (0.3)	1 (0.2)	1 (2.9)
Cycle 1 day 8				
n	532	275	414	33
Any grade	154 (28.9)	106 (38.5)	155 (37.4)	10 (30.3)
Grade 1	68 (12.8)	35 (12.7)	49 (11.8)	2 (6.1)
Grade 2	64 (12.0)	43 (15.6)	65 (15.7)	4 (12.1)
Grade 3	16 (3.0)	17 (6.2)	27 (6.5)	1 (3.0)
Grade 4	6 (1.1)	11 (4.0)	14 (3.4)	3 (9.1)
Cycle 2 day 8				
n	507	266	393	28
Any grade	77 (15.2)	59 (22.2)	83 (21.1)	4 (14.3)
Grade 1	42 (8.3)	31 (11.7)	40 (10.2)	2 (7.1)
Grade 2	29 (5.7)	22 (8.3)	33 (8.4)	2 (7.1)
Grade 3	6 (1.2)	3 (1.1)	6 (1.5)	0
Grade 4	0	3 (1.1)	4 (1.0)	0
Cycle 3 day 8				
n	427	222	320	26
Any grade	66 (15.5)	42 (18.9)	56 (17.5)	4 (15.4)
Grade 1	38 (8.9)	21 (9.5)	27 (8.4)	3 (11.5)
Grade 2	20 (4.7)	16 (7.2)	21 (6.6)	1 (3.8)
Grade 3	7 (1.6)	4 (1.8)	6 (1.9)	0
Grade 4	1 (0.2)	1 (0.5)	2 (0.6)	0

Percentages based on the number of subjects with nonmissing data at each visit within each

laboratory test.

Group A, no liver impairment; group B, increased AST and/or ALT only; group C, any abnormality except increased bilirubin; group D, increased bilirubin.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events.